Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Inclusion Criteria:

1. The patient must have good compliance, be understood the research process of this study and required to sign an informed consent form;
2. age 18-75 years old, male or female;
3. Histopathologically confirmed intrahepatic cholangiocarcinoma，excluding mixed liver cancer;
4. The longest diameter of a single tumor in patients before surgery is 3\~9cm. If the number of multiple tumors is ≤3, the total diameter≤9cm, maximum diameter ≤5cm;
5. Study treatment can be started within 4\~6 weeks after R0 resection;
6. Except for R0 resection, no other anti-tumor treatment has been received;
7. No distant transfer；
8. ECOG\<2, or KPS\>70；
9. Bone marrow function criteria: hemoglobin (HGB)≥90g/L; absolute neutrophil count (ANC)≥1.5×109/L; platelets (PLT)≥100×109/L;
10. Liver function criteria: ALT, AST≤5×ULN, serum total bilirubin\<3×ULN;
11. Renal function criteria: creatinine clearance \> 45 mL/min
12. Prothrombin time \<14s; (no anticoagulant therapy);
13. Patients without biliary obstruction who require biliary stent implantation must be completed at least 7 days prior to enrollment;
14. Non-lactating or pregnant women, contraception during or after 6 months of treatment.
15. No contraindications for gemcitabine and Nab-paclitaxel.

Exclusion Criteria:

1. Those patients who are allergic to the chemotherapy drugs and their components in this study
2. Patients with other malignant tumors within 5 years (except for cured carcinoma in situ or basal cell carcinoma of the skin)
3. Concomitant diseases that may interfere with treatment studies: such as severe infections, HIV-positive, clinically severe (ie active) Heart disease, uncontrolled epilepsy, central nervous system disease, or history of mental disorders;
4. Intraoperative or postoperative pathology determines patients who do not meet radical resection;
5. Patients with current or previous ≥ grade II peripheral neuropathy;
6. Patients who participated in other clinical studies within 4 weeks prior to enrollment;
7. Patients who has undergone organ transplantation;
8. Patients considered by the investigator not suitable for this trial.